Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-cell Neoplasms

PURPOSE: A phase I study was conducted to determine the dose-limiting toxicities (DLT) and maximally tolerated dose (MTD) for the combination of bortezomib and alvocidib in patients with B cell malignancies (multiple myeloma, indolent and mantle cell lymphoma). EXPERIMENTAL DESIGN: Patients received...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Holkova, Beata, Perkins, E. Brent, Ramakrishnan, Viswanathan, Tombes, Mary Beth, Shrader, Ellen, Talreja, Neha, Wellons, Martha D., Hogan, Kevin T., Roodman, G. David, Coppola, Domenico, Kang, Loveleen, Dawson, Jana, Stuart, Robert K., Peer, Cody, Figg, William D., Kolla, Sarah, Doyle, Austin, Wright, John, Sullivan, Daniel M., Roberts, John D., Grant, Steven
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3096752/
https://ncbi.nlm.nih.gov/pubmed/21447728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2876
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados